These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 20625580

  • 1. Genetic approach to evaluate specificity of small molecule drug candidates inhibiting PLK1 using zebrafish.
    Zhong H, Xin S, Zhao Y, Lu J, Li S, Gong J, Yang Z, Lin S.
    Mol Biosyst; 2010 Aug; 6(8):1463-8. PubMed ID: 20625580
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).
    Uckun FM, Dibirdik I, Qazi S, Vassilev A, Ma H, Mao C, Benyumov A, Emami KH.
    Bioorg Med Chem; 2007 Jan 15; 15(2):800-14. PubMed ID: 17098432
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Targeting Polo-like kinase in cancer therapy.
    Degenhardt Y, Lampkin T.
    Clin Cancer Res; 2010 Jan 15; 16(2):384-9. PubMed ID: 20068088
    [Abstract] [Full Text] [Related]

  • 6. A novel anti-tumor inhibitor identified by virtual screen with PLK1 structure and zebrafish assay.
    Lu J, Xin S, Meng H, Veldman M, Schoenfeld D, Che C, Yan R, Zhong H, Li S, Lin S.
    PLoS One; 2013 Jan 15; 8(4):e53317. PubMed ID: 23658603
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y, Huang D, Zhang Z, Smith J, Petillo D, Looyenga BD, Feenstra K, Mackeigan JP, Furge KA, Teh BT.
    Cancer Res; 2011 Aug 01; 71(15):5225-34. PubMed ID: 21642374
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
    Johnson EF, Stewart KD, Woods KW, Giranda VL, Luo Y.
    Biochemistry; 2007 Aug 21; 46(33):9551-63. PubMed ID: 17655330
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
    Strebhardt K, Becker S, Matthess Y.
    Expert Opin Drug Discov; 2015 Jan 21; 10(1):1-8. PubMed ID: 25263688
    [Abstract] [Full Text] [Related]

  • 15. Polo and Aurora kinases: lessons derived from chemical biology.
    Taylor S, Peters JM.
    Curr Opin Cell Biol; 2008 Feb 21; 20(1):77-84. PubMed ID: 18249108
    [Abstract] [Full Text] [Related]

  • 16. Polo-like kinase controls vertebrate spindle elongation and cytokinesis.
    Brennan IM, Peters U, Kapoor TM, Straight AF.
    PLoS One; 2007 May 02; 2(5):e409. PubMed ID: 17476331
    [Abstract] [Full Text] [Related]

  • 17. A fluorescence polarization assay for the discovery of inhibitors of the polo-box domain of polo-like kinase 1.
    Reindl W, Strebhardt K, Berg T.
    Methods Mol Biol; 2012 May 02; 795():69-81. PubMed ID: 21960216
    [Abstract] [Full Text] [Related]

  • 18. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis.
    Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T.
    Chembiochem; 2009 May 04; 10(7):1145-8. PubMed ID: 19350612
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
    Schöffski P.
    Oncologist; 2009 Jun 04; 14(6):559-70. PubMed ID: 19474163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.